Macro Group Pharmaceuticals (Macro Capital) S.A.E reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was EGP 252.3 million compared to EGP 215.17 million a year ago. Net income was EGP 68.75 million compared to EGP 58.1 million a year ago. Basic earnings per share from continuing operations was EGP 0.12 compared to EGP 0.1 a year ago. Diluted earnings per share from continuing operations was EGP 0.12 compared to EGP 0.1 a year ago.
For the nine months, sales was EGP 589.53 million compared to EGP 520.3 million a year ago. Net income was EGP 98.09 million compared to EGP 129.45 million a year ago. Basic earnings per share from continuing operations was EGP 0.17 compared to EGP 0.23 a year ago. Diluted earnings per share from continuing operations was EGP 0.17 compared to EGP 0.23 a year ago.